KRAS and neoplasm: When only KRAS WT cases were analyzed patients whose tumours carried the BRAF mutation had even more significantly lower TTP and OS (TTP: 2.1 vs. 6.4 months, p<0.0001; OS: 4.3 vs. 16.3 months, p <0.0001) (Figure 3C and 3D) compared with the results in the whole population.